Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roivant
Biotech
Roivant reports phase 3 autoimmune win for ex-Pfizer asset
A phase 3 trial of Priovant's brepocitinib has hit its primary endpoint, setting the Roivant biotech up to seek approval for the TYK2/JAK1 inhibitor.
Nick Paul Taylor
Sep 17, 2025 7:00am
Revised Blueprint-VantAI deal turns focus to molecular glues
May 20, 2025 10:32am
Galapagos CEO eyes exit as spinout names leader—Chutes & Ladders
Apr 25, 2025 8:30am
Immunovant narrows R&D focus as Roivant execs join C-suite
Apr 21, 2025 10:00am
Immunovant posts phase 3 autoimmune win but won't seek approval
Mar 19, 2025 9:15am
Big Pharma layoff rounds jump 281% in 2024
Jan 3, 2025 3:29pm
